Alterations of mast cells and TGF-&beta;1 on the silymarin treatment for CCl4-induced hepatic fibrosis

doi:10.3748/wjg.v11.i8.1141

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4958)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-2) series.

Item

Count

PDF

472

HTML

4130

Figures (1-6)

218

Tables (1-2)

138

Sum=4958

Feb 28, 2005 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (68)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Feb 28, 2005; 11(8): 1141-1148
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1141

Full Size Figure Download Figure

Figure 6 Recruitment of mast cell numbers in only CCl₄- or CCl₄ with silymarin-treated groups. At 4, 8 and 12 wk, mast cell numbers of CCl₄ with silymarin-treated group (black bar) significantly reduced compared to those of control group (open bar). Data are expressed as the mean±SD. ^aP<0.05 means significant compared to that of CCl₄-treated groups. ^cP<0.005 smeans significant compared to that of CCl₄-treated groups.

Citation: Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS. Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl₄-induced hepatic fibrosis. World J Gastroenterol 2005; 11(8): 1141-1148
URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1141.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1141